Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Pharmacopsychiatry ; 42(1): 14-9, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19153941

ABSTRACT

INTRODUCTION: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients. METHODS: Thirty patients taking olanzapine (10-20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12. RESULTS: The rosiglitazone and placebo groups gained 3.2+/-4.5 and 2.2+/-2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels. DISCUSSION: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.


Subject(s)
Antipsychotic Agents/adverse effects , Benzodiazepines/adverse effects , Hypoglycemic Agents/therapeutic use , Metabolic Diseases/chemically induced , Metabolic Diseases/drug therapy , Thiazolidinediones/therapeutic use , Adult , Body Mass Index , Body Weight/drug effects , Double-Blind Method , Female , Fibrinogen/metabolism , Hemoglobins/metabolism , Humans , Insulin Resistance , Lipid Metabolism/drug effects , Male , Middle Aged , Olanzapine , Pilot Projects , Rosiglitazone , Schizophrenia/drug therapy , Statistics as Topic
2.
Cardiology ; 88(3): 254-7, 1997.
Article in English | MEDLINE | ID: mdl-9129846

ABSTRACT

In order to determine whether electroconvulsive therapy (ECT) alters left-ventricular function in patients without heart disease, we studied 11 patients who had a normal cardiovascular system and were submitted to ECT. Left-ventricular function was assessed by means of a clinical examination and an echocardiographic evaluation performed before the ECT and 20 min and 6 h after ECT. Twenty minutes after ECT, the patients' end-systolic volume was increased (p = 0.003), whereas the ejection fraction (p = 0.004) and E to A ratio were decreased (p = 0.004 and 0.028, respectively). These indexes returned to the normal control value 6 h later. None of our patients presented any clinical signs of heart failure. We conclude that in some patients, ECT produces a significant and transient decrease in left-ventricular systolic and diastolic function.


Subject(s)
Electroconvulsive Therapy , Ventricular Function, Left/physiology , Adult , Blood Pressure , Diastole , Echocardiography, Doppler , Electrocardiography , Female , Follow-Up Studies , Heart Diseases , Heart Rate , Heart Ventricles/diagnostic imaging , Humans , Male , Mental Disorders/physiopathology , Mental Disorders/therapy , Systole
SELECTION OF CITATIONS
SEARCH DETAIL